

Michelle Whirl-Carrillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8337095/publications.pdf>

Version: 2024-02-01

54
papers

7,741
citations

109264

35
h-index

161767

54
g-index

58
all docs

58
docs citations

58
times ranked

9674
citing authors

#	ARTICLE	IF	CITATIONS
1	Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. <i>Cell</i> , 2012, 148, 1293-1307.	13.5	1,134
2	The BioPAX community standard for pathway data sharing. <i>Nature Biotechnology</i> , 2010, 28, 935-942.	9.4	613
3	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <i>TPMT</i> and <i>NUDT15</i> Genotypes: 2018 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1095-1105.	2.3	428
4	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Genetics in Medicine</i> , 2017, 19, 215-223.	1.1	410
5	Clinical Interpretation and Implications of Whole-Genome Sequencing. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1035.	3.8	398
6	Prediction of CYP2D6 phenotype from genotype across world populations. <i>Genetics in Medicine</i> , 2017, 19, 69-76.	1.1	365
7	Standardizing <i>CYP2D6</i> Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , 2020, 13, 116-124.	1.5	353
8	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	0.7	341
9	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (<i>CYP</i>) Allele Nomenclature Database. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 399-401.	2.3	335
10	An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 563-572.	2.3	308
11	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
12	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
13	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 171-175.	2.3	207
14	PharmGKB: A worldwide resource for pharmacogenomic information. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1417.	6.6	205
15	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 207-210.	2.3	164
16	PharmVar GeneFocus: <i>CYP2D6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 154-170.	2.3	156
17	From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. <i>Biomarkers in Medicine</i> , 2011, 5, 795-806.	0.6	145
18	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. <i>PLoS Genetics</i> , 2011, 7, e1002280.	1.5	137

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz-Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	2.3	125
20	PharmVar GeneFocus: <i>CYP2B6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 82-97.	2.3	108
21	The Evolution of PharmVar. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 29-32.	2.3	106
22	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA-B</i> Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 302-309.	2.3	102
23	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1256-1262.	2.3	90
24	Recommendations for Clinical <i>CYP2C9</i> Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 746-755.	1.2	84
25	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1977-1985.	0.5	79
26	Pharmacogenetics at Scale: An Analysis of the UK Biobank. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1528-1537.	2.3	78
27	Recommendations for Clinical <i>CYP2D6</i> Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1047-1064.	1.2	73
28	PharmVar GeneFocus: <i>CYP2C19</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 352-366.	2.3	72
29	Pharmacogenomics Clinical Annotation Tool (PharmCAT). <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 203-210.	2.3	65
30	Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 542-545.	2.3	62
31	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. <i>Pharmacogenomics</i> , 2018, 19, 847-860.	0.6	53
32	PharmVar and the Landscape of Pharmacogenetic Resources. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 43-46.	2.3	50
33	Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on <i>MT-RNR1</i> Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 366-372.	2.3	50
34	Pharmacogene Variation Consortium Gene Introduction: <i>NUDT15</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1091-1094.	2.3	45
35	Recommendations for Clinical Warfarin Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 847-859.	1.2	39
36	PharmVar GeneFocus: <i>CYP2C9</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 662-676.	2.3	34

#	ARTICLE	IF	CITATIONS
37	PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge. <i>Current Protocols</i> , 2021, 1, e226.	1.3	33
38	Transfer learning enables prediction of CYP2D6 haplotype function. <i>PLoS Computational Biology</i> , 2020, 16, e1008399.	1.5	32
39	Pharmacogenomics and big genomic data: from lab to clinic and back again. <i>Human Molecular Genetics</i> , 2018, 27, R72-R78.	1.4	28
40	Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 284-286.	2.3	27
41	Mining biochemical information: Lessons taught by the ribosome. <i>Rna</i> , 2002, 8, 279-289.	1.6	25
42	Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. <i>PLoS Genetics</i> , 2015, 11, e1005496.	1.5	23
43	Using ODIN for a PharmGKB revalidation experiment. <i>Database: the Journal of Biological Databases and Curation</i> , 2012, 2012, bas021-bas021.	1.4	18
44	PharmVar GeneFocus: <i>CYP3A5</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1159-1171.	2.3	14
45	In silico comparative characterization of pharmacogenomic missense variants. <i>BMC Genomics</i> , 2014, 15, S4.	1.2	11
46	PGxMine: Text mining for curation of PharmGKB. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2020, 25, 611-622.	0.7	9
47	PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 116-122.	2.3	6
48	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 559-562.	2.3	6
49	Variant Interpretation in Current Pharmacogenetic Testing. <i>Journal of Personalized Medicine</i> , 2020, 10, 204.	1.1	5
50	Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. <i>Pharmacological Research</i> , 2020, 158, 104838.	3.1	2
51	PharmGKB summary: acyclovir/ganciclovir pathway. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 201-208.	0.7	2
52	An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2022, 27, 385-396.	0.7	1
53	Bioinformatics: Accumulating and implementing pharmacogenomics information. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, S6.	1.1	0
54	Scientific evidence and sources of knowledge for pharmacogenomics. , 2022, , 19-51.		0